Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly

European Journal of Endocrinology

Volumn 155, Issue 1, 2006, Pages 73-78

  Steffin, Birgit ^b   Gutt, B ^a   Bidlingmaier, M ^b   Dieterle, C ^b   Oltmann, F ^b   Schopohl, J ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GLUCOSE; GROWTH HORMONE; INSULIN; LONG ACTING DRUG; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GROWTH HORMONE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPOPHYSECTOMY; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

ACROMEGALY; ADULT; AGED; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; GELS; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; SOMATOSTATIN;

EID: 33746273283     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02185     Document Type: Article

References (17)

1. Colao A, Ferone D, Marzullo P & Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 2004 25 102-152.
2. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN & Underwood LE. Evaluation of acromegaly by radio-immunoassay of somatomedin-C. New England Journal of Medicine 1979 301 1138-1142.
3. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T & Arita N. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clinical Endocrinology (Oxford) 2000 52 549-555.
4. Jaffrain-Rea ML, Moroni C, Baldelli R, Battista C, Maffei P, Terzolo M, Correra M, Ghiggi MR, Ferretti E, Angeli A, Sicolo N, Trischitta V, Liuzzi A, Cassone R & Tamburrano G. Relationship between blood pressure and glucose tolerance in acromegaly. Clinical Endocrinology (Oxford) 2001 54 189-195.
5. Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P & Arosio M. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. Journal of Endocrinological Investigation 2002 25 502-507.
6. World Health Organization definition, diagnosis and classification of diabetes mellitus and its complications. 1999.
7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
8. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Petretta M, Salvatore M & Lombardi G. Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. Journal of Clinical Endocrinology and Metabolism 1999 84 1518-1523.
9. Wallace TM, Levy JC & Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004 27 1487-1495.
10. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V & Tamburrano G. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clinical Endocrinology (Oxford) 2003 59 492-499.
11. Ho KK, Jenkins AB, Furler SM, Borkman M & Chisholm DJ. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clinical Endocrinology (Oxford) 1992 36 271-279.
12. Breidert M, Pinzer T, Wildbrett J, Bornstein SR & Hanefeld M. Long-term effect of octreotide in acromegaly on insulin resistance. Hormone and Metabolic Research 1995 27 226-230.
13. Verschoor L, Lamberts SW, Uitterlinden P & Del Pozo E. Glucose tolerance during long term treatment with a somatostatin analogue. British Medical Journal (Clinical Research Edition) 1986 293 1327-1328.
14. Quabbe HJ & Plockinger U. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. Journal of Clinical Endocrinology and Metabolism 1989 68 873-881.
15. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RI, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
16. Rose DR & Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Hormone and IGF Research 2002 12 418-424.
17. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP & Trainer PJ. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. European Journal of Endocrinology 2003 149 521-527.